Target
HLA-G
4 abstracts
Abstract
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.Org: University of Okahoma Health Sciences Center,
Abstract
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.Org: Bayer AG, Charité - Universitätsmedizin Berlin, Berlin, Germany, University of Munich, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Germany,
Abstract
Prognostic value of human leukocyte antigen G (HLA-G) expression in solid tumors: A systematic review and meta-analysis.Org: Hospital Clinico San Carlos, IdISSC, Velindre Cancer Centre, Velindre University NHS Trust, Clinica Universidad de Navarra, Princess Margaret Cancer Centre,
Abstract
Immunohistochemical analysis of the tumor microenvironment in acral lentiginous melanoma (ALM).Org: USC Keck School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, USC Norris Cancer Hospital, Los Angeles, CA, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,